scholarly journals Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Siang-Boon Koh ◽  
Brian N. Dontchos ◽  
Veerle Bossuyt ◽  
Christine Edmonds ◽  
Simona Cristea ◽  
...  

AbstractSystematic collection of fresh tissues for research at the time of diagnostic image-guided breast biopsy has the potential to fuel a wide variety of innovative studies. Here we report the initial experience, including safety, feasibility, and laboratory proof-of-principle, with the collection and analysis of research specimens obtained via breast core needle biopsy immediately following routine clinical biopsy at a single institution over a 14-month period. Patients underwent one or two additional core biopsies following collection of all necessary clinical specimens. In total, 395 patients were approached and 270 consented to the research study, yielding a 68.4% consent rate. Among consenting patients, 238 lesions were biopsied for research, resulting in 446 research specimens collected. No immediate complications were observed. Representative research core specimens showed high diagnostic concordance with clinical core biopsies. Flow cytometry demonstrated consistent recovery of hundreds to thousands of viable cells per research core. Among a group of HER2 + tumor research specimens, HER2 assessment by flow cytometry correlated highly with immunohistochemistry (IHC) staining, and in addition revealed extensive inter- and intra-tumoral variation in HER2 levels of potential clinical relevance. Suitability for single-cell transcriptomic analysis was demonstrated for a triple-negative tumor core biopsy, revealing substantial cellular diversity in the tumor immune microenvironment, including a prognostically relevant T cell subpopulation. Thus, collection of fresh tissues for research purposes at the time of diagnostic breast biopsy is safe, feasible and efficient, and may provide a high-yield mechanism to generate a rich tissue repository for a wide variety of cross-disciplinary research.

1986 ◽  
Vol 72 (2) ◽  
pp. 171-177 ◽  
Author(s):  
Raffaella Uccelli ◽  
Alberto Calugi ◽  
Donato Forte ◽  
Francesco Mauro ◽  
Paolo Polonio-Balbi ◽  
...  

The relative DNA content of cellular samples from 54 patients affected by breast carcinomas and 20 affected by benign breast lesions (including 11 fibroadenomas) was measured by flow cytometry. All normal tissue samples and 17/20 (85%) specimens from benign lesions exhibited a cytometrically diploid DNA distribution, 3/20 (15%) benign lesions an abnormal DNA content, and 35/54 (65%) carcinomas at least one aneuploid cell subpopulation. Furthermore, 9/54 (17%) tumors were characterized by the presence of more than one aneuploid cell subpopulation. The results also indicate that flow cytometry can be used to recognize lymph nodes infiltrated by aneuploid cells. Statistically significant correlations were evidenced between the occurrence of aneuploidy or the ploidy level measured as DNA index and the nodal infiltration status. The percentage of S cells can also be extracted from DNA content distribution histograms. Statistically significant differences (p < 0.01) were also observed for the percentage of S cells between normal tissues (6.2±3.2 SD) and benign lesions (11.1±6.6 SD), normal tissues (6.2 ± 3.2 SD) and aneuploid tumors (19.7 ± 10.3 SD), benign lesions (11.1 ± 6.6 SD) and aneuploid tumors (19.7 ± 10.3 SD), and diploid (7.9 ± 4.0 SD) and aneuploid tumors (19.7 ± 10.3 SD).


2020 ◽  
Vol 5 (2) ◽  
pp. 55-60
Author(s):  
Nurul Issttifa Aminuddin ◽  
Raihana Edros ◽  
Rajaletchumy Veloo Kutty

Triple negative breast cancer (TNBC) is a very aggressive type of cancer.  TNBC is not just a single type of disease to be cured, but it consists of 6 subtypes which are basal-like 1 and 2, immunomodulatory, mesenchymal, mesenchymal stem- like and luminar androgen receptor. These subtypes has diverse characteristics, which hold potential opportunity for targeted treatment. Lack of molecular targets for triple negative tumor lead to limited targeted therapies for TNBC.  Therefore, effective targeted therapies are urgently needed for TNBC. This paper will highlight on the potential targets in TNBC and treatment options that are currently under clinical application.  


2019 ◽  
Author(s):  
Wei Wang ◽  
Yan Li ◽  
Lan Ma ◽  
Wen-Qing Hu ◽  
Bin Jiang

Abstract Background We detected the expression of CD25 in patients with acute myeloid leukemia (AML) to value whether CD25 could be a promising marker for minimal residual disease (MRD). Methods Two hundred and twenty bone marrow (BM) specimens from 98 adult patients with AML after chemotherapy were detected using flow cytometry. The expression of CD25 was compared between MRD positive and negative subgroups. Results About 38% of patients with MRD were positive for CD25. The mean percentage of CD25-positive cell subpopulation was 58.68% relative to the whole MRD cluster (0.05%-100%). The mean fluorescence index ratio (MFIR) of CD25 in these cell subpopulations was approximately13-fold greater than that in normal myeloblasts. The detection sensitivity of CD25 was as high as 10 -4 . CD25 was also expressed on non-leukemic stem cells that were positive for CD34 and CD38. Conclusion CD25, as assessed by flow cytometry, is a promising marker for MRD in patients with AML.


Nanomedicine ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. 391-400
Author(s):  
Yan Li ◽  
Xiang Chen ◽  
Qiannan Zhu ◽  
Rui Chen ◽  
Lu Xu ◽  
...  

Aim: To compare the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy (NST) for breast cancer. Materials & methods: Patients (n = 201) received NST comprising either dose-dense epirubicin and cyclophosphamide followed by 2-weekly nP (n = 104) or 3-weekly courses of epirubicin and cyclophosphamide followed by docetaxel (n = 97). Results: Higher pathological complete response rates were achieved by the nP group. Subgroup analysis showed that the nP-based regimen achieved higher pathological complete response rates in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3–4 peripheral sensory neuropathies were more frequent in the nP group. Conclusion: The 2-weekly nP-based regimen might be a better choice of NST for patients with breast cancer.


2012 ◽  
Vol 209 (4) ◽  
pp. 679-696 ◽  
Author(s):  
Dai Horiuchi ◽  
Leonard Kusdra ◽  
Noelle E. Huskey ◽  
Sanjay Chandriani ◽  
Marc E. Lenburg ◽  
...  

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor prognosis. We exploit the increased MYC expression found in triple-negative breast cancers by using a synthetic-lethal approach dependent on cyclin-dependent kinase (CDK) inhibition. CDK inhibition effectively induced tumor regression in triple-negative tumor xenografts. The proapoptotic BCL-2 family member BIM is up-regulated after CDK inhibition and contributes to this synthetic-lethal mechanism. These results indicate that aggressive breast tumors with elevated MYC are uniquely sensitive to CDK inhibitors.


Sign in / Sign up

Export Citation Format

Share Document